Other
D5W Placebo
D5W Placebo is an intervention with 3 clinical trials. Historical success rate of 100.0%.
Total Trials
3
Max Phase
—
Type
OTHER
Molecule
—
Success Metrics
Clinical Success Rate
100.0%
Based on 2 completed trials
Completion Rate
100%(2/2)
Active Trials
0(0%)
Results Posted
50%(1 trials)
Phase Distribution
Ph phase_2
1
33%
Ph phase_3
2
67%
Phase Distribution
0
Early Stage
1
Mid Stage
2
Late Stage
Phase Distribution3 total trials
Phase 2Efficacy & side effects
1(33.3%)
Phase 3Large-scale testing
2(66.7%)
Highest Phase Reached
Phase 3Trial Status & Enrollment
Completion Rate
100.0%
2 of 2 finished
Non-Completion Rate
0.0%
0 ended early
Currently Active
0
trials recruiting
Total Trials
3
all time
Status Distribution
Completed(2)
Other(1)
Detailed Status
Completed2
unknown1
Development Timeline
Analytics
Development Status
Total Trials
3
Active
0
Success Rate
100.0%
Most Advanced
Phase 3
Trials by Phase
Phase 21 (33.3%)
Phase 32 (66.7%)
Trials by Status
completed267%
unknown133%
Recent Activity
0 active trials
Showing 3 of 3
completedphase_3
Plinabulin vs. Pegfilgrastim in Patients With Solid Tumors Receiving Docetaxel Myelosuppressive Chemotherapy Phase 3
NCT03102606
unknownphase_3
Plinabulin vs. Pegfilgrastim in Prevention of TAC Induced Neutropenia
NCT03294577
completedphase_2
N-Acetylcysteine in Critically Ill Patients Undergoing Contrast Enhanced Computed Tomography
NCT00830193
Clinical Trials (3)
Showing 3 of 3 trials
NCT03102606Phase 3
Plinabulin vs. Pegfilgrastim in Patients With Solid Tumors Receiving Docetaxel Myelosuppressive Chemotherapy Phase 3
NCT03294577Phase 3
Plinabulin vs. Pegfilgrastim in Prevention of TAC Induced Neutropenia
NCT00830193Phase 2
N-Acetylcysteine in Critically Ill Patients Undergoing Contrast Enhanced Computed Tomography
All 3 trials loaded
Drug Details
- Intervention Type
- OTHER
- Total Trials
- 3